Loading patent…
AssigneeRoche Glycart AG
InventorsOliver Ast, Peter Bruenker, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Pablo Umana
Estimating the term…
The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.
An immunoconjugate comprising a first and a second antigen binding moiety, and an Fc domain consisting of two subunits, and an effector moiety, wherein the effector moiety is a cytokine, wherein not more than one effector moiety is present, and further wherein said Fc domain comprises a modification promoting heterodimerization of two non-identical polypeptide chains.
Dependencies are inferred from the claim text.